We gebruiken cookies om ervoor te zorgen dat onze site zo soepel mogelijk draait. Als je doorgaat met het gebruiken van deze site, gaan we er vanuit dat je ermee instemt.
To the Editor Puymirat and colleagues report the APERITIF randomized clinical trial evaluating rivaroxaban, 2.5 mg, twice daily for 4 weeks added to dual antiplatelet therapy (DAPT) to prevent left ventricular (LV) thrombus after anterior ST-segment elevation myocardial infarction (STEMI). The primary end point—LV thrombus on contrast-enhanced cardiac magnetic resonance (CMR) at 1 month—was neutral, while minor bleeding (Bleeding Academic Research Consortium [BARC] type 1) was increased in the rivaroxaban group.
This randomized clinical trial analyzes whether finerenone lowers blood pressure and whether its cardiovascular benefits in patients with mildly reduced or preserved ejection fraction heart failure depend on baseline blood pressure or blood-pressure reduction.
Onderwerpen
Blogs
3 dagen geleden
